Screening for depression

Extract

1 Translation of the key statement of the final report S16-05 Screening auf Depression (Version 1.0; Status: 27 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding.
Publishing details

Publisher:
Institute for Quality and Efficiency in Health Care

Topic:
Screening for depression

Commissioning agency:
Federal Joint Committee

Commission awarded on:
27 April 2016

Internal Commission No.:
S16-05

Address of publisher:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Im Mediapark 8
50670 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
E-mail: berichte@iqwig.de
Internet: www.iqwig.de
This report was prepared in collaboration with external experts. The responsibility for the contents of the report lies solely with IQWiG.

According to §139b (3) No. 2 of Social Code Book (SGB) V, Statutory Health Insurance, external experts who are involved in the Institute’s research commissions must disclose “all connections to interest groups and contract organizations, particularly in the pharmaceutical and medical devices industries, including details on the type and amount of any remuneration received”. The Institute received the completed Form for disclosure of potential conflicts of interest from each external expert. The information provided was reviewed by a Committee of the Institute specifically established to assess conflicts of interests. The information on conflicts of interest provided by the external experts and external reviewers is presented in Chapter A8 of the full report. No conflicts of interest were detected that could endanger professional independence with regard to the work on the present commission.

**External experts**
- Katharina Antony (from August 2017), Gesundheit Österreich (Health Austria) GmbH, Vienna, Austria
- Borwin Bandelow, Hospital for Psychiatry and Psychotherapy, University of Göttingen, Germany
- Barbara Fröschl (up to November 2017), Gesundheit Österreich (Health Austria) GmbH, Vienna, Austria
- Bernhard Kis, Hospital for Psychiatry and Psychotherapy, University of Göttingen, Germany
- Anja Laschkolnig, Gesundheit Österreich (Health Austria) GmbH, Vienna, Austria
- Brigitte Piso, Gesundheit Österreich (Health Austria) GmbH, Vienna, Austria
- Heidi Stürzlinger, Gesundheit Österreich (Health Austria) GmbH, Vienna, Austria
- Sarah Trost, Hospital for Psychiatry and Psychotherapy, University of Göttingen, Germany

IQWiG thanks the external experts for their collaboration in the project.

**IQWiG employees**
- Martina Markes
- Elke Hausner
- Julia Kreis
- Sibylle Sturtz

**Keywords:** Mass Screening, Depressive Disorder, Benefit Assessment, Systematic Review
Key statement

Research question
The aim of this report is to assess the benefit of systematic screening for depression in primary care when compared to no screening with regard to patient-relevant outcomes.

Conclusion
The 7 included studies on the screening chain, most of which were conducted in Japan, investigated the outcomes suicide and depression (extent of symptoms and prevalence). From these studies, it was not possible to derive a hint of benefit of screening for depression for either outcome.

No usable data were available for assessing the benefit of early versus later treatment of patients with depression detected by the screening.

Overall, there is no hint of benefit or harm of systematic screening for depression.

The full report (German version) is published under https://www.iqwig.de/de/projekte-ergebnisse/projekte-301/nichtmedikamentoese-verfahren/s-projekte/s16-05-screening-auf-depression.7850.html